Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$7.35
$7.29
$3.27
▼
$7.45
$2.73B1.5413.29 million shsN/A
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
$7.98
-3.5%
$11.79
$4.88
▼
$15.87
$1.13B2.433.50 million shs2.69 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
0.00%0.00%0.00%+0.82%+83.75%
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
-8.21%-9.91%-23.07%-40.50%+59.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$7.35
$7.29
$3.27
▼
$7.45
$2.73B1.5413.29 million shsN/A
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
$7.98
-3.5%
$11.79
$4.88
▼
$15.87
$1.13B2.433.50 million shs2.69 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
0.00%0.00%0.00%+0.82%+83.75%
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
-8.21%-9.91%-23.07%-40.50%+59.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
2.07
Hold$10.5643.62% Upside
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
2.88
Moderate Buy$23.14190.01% Upside

Current Analyst Ratings Breakdown

Latest ATAI and CMPS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
Reiterated RatingBuy
11/9/2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
Reiterated RatingBuy
11/4/2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
Reiterated RatingOutperform
11/4/2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
Lower Price TargetEqual Weight$13.00 ➝ $10.00
11/3/2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
Reiterated RatingOutperform$20.00
11/3/2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
Reiterated RatingBuy$25.00
10/15/2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
Reiterated RatingSell (D-)
9/22/2026
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
Dropped CoverageNeutral
9/9/2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
Reiterated RatingBuy
8/17/2026
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
DowngradeOutperform ➝ Market Perform
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$4.09M666.46N/AN/A$0.69 per share10.65
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
N/AN/AN/AN/A$1.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
-$660.05M-$2.18N/AN/AN/A-14,938.36%-88.30%-58.88%N/A
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
-$287.86M-$3.49N/AN/AN/AN/A-18.03%-5.11%N/A

Latest ATAI and CMPS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
-$0.39-$0.31+$0.08-$0.31N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
N/AN/AN/AN/AN/A
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
N/AN/AN/A
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
0.35
1.50
1.50

Institutional Ownership

CompanyInstitutional Ownership
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
28.41%
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
46.19%

Insider Ownership

CompanyInsider Ownership
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
19.80%
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
2.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
80370.86 million297.43 millionOptionable
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
156141.71 million137.71 millionOptionable

Recent News About These Companies

HC Wainwright Lifts Earnings Estimates for Compass Pathways
Compass Pathways (NASDAQ:CMPS) Upgraded at Wall Street Zen
Equities Analysts Offer Predictions for CMPS FY2026 Earnings
HC Wainwright Reaffirms Buy Rating for Compass Pathways (NASDAQ:CMPS)
Wall Street Zen Upgrades Compass Pathways (NASDAQ:CMPS) to Sell

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atai Beckley stock logo

Atai Beckley NASDAQ:ATAI

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Compass Pathways stock logo

Compass Pathways NASDAQ:CMPS

$7.98 -0.29 (-3.51%)
Closing price 04:00 PM Eastern
Extended Trading
$8.12 +0.14 (+1.69%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.